Groundbreaking COPD Therapy: CTTQ PHARMA‘S TQC3721 Suspension Cleared for Phase III Trial
Time:2025-07-01
Views:3
CTTQ PHARMA recently announced that its inhaled PDE3/4 dual inhibitor TQC3721 suspension has received approval from China’s Center for Drug Evaluation (CDE) to initiate Phase III clinical trials for COPD maintenance therapy. As the world’s first inhaled formulation concurrently targeting PDE3 (bronchodilation) and PDE4 (anti-inflammatory) pathways, TQC3721 may offer a novel alternative to traditional triple therapy for moderate-to-severe COPD patients.
Chronic Obstructive Pulmonary Disease (COPD), a severe chronic respiratory disorder, currently utilizes bronchodilators and inhaled corticosteroids as first-line treatments. These therapies provide symptomatic relief and slow disease progression in stable-phase management, with dozens of single/combination inhaled products available, including:
(1) Long-acting beta2 agonist : the duration of action lasts for more than 12h, the early-generation are Salmeterol, Formoterol, the new LABA such as indanterol, odatrol and vilanterol etc. have faster onset of action, and longer duration of action.
(2) Long-acting anti-muscarinic: enable persistently bind M3 receptors, rapid separation from M2 receptors, thus prolonging the bronchodilator action time of more than 12h, the new type of LAMA action time of more than 24h, the commonly used LAMA including Tiotropium bromide, Umeclidinium bromide etc.
Addressing these R&D and manufacturing challenges, SZEB supplies comprehensive impurity reference standards, including process-related impurities and degradation products (e.g., oxidative/hydrolytic breakdown compounds),enabling robust quality control of inhaled drug products.
Full impurity specifications: www.ex-biotech.com
Custom solutions & quotations: sales@e-biotech.com
Custom solutions & quotations: sales@e-biotech.com
.jpg)
Wechat
Jolin
Yuzhu Lin
Ciel Wong
whatsapp